Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$8.60 +1.7%	$11.66	$5.26 ▼ $17.17	$822.50M	1.27	82,588 shs	56,254 shs
ELVN Enliven Therapeutics	$18.73 -0.4%	$20.68	$13.30 ▼ $30.03	$922.99M	0.93	376,154 shs	490,125 shs
GPCR Structure Therapeutics	$17.59 -1.2%	$20.43	$13.22 ▼ $45.37	$1.02B	-1.87	728,968 shs	571,199 shs
UPXI Upexi	$4.60 -0.9%	$7.42	$1.90 ▼ $22.57	$414.19M	-0.58	12.72 million shs	5.52 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	+1.65%	-17.70%	-11.89%	-26.50%	+859,999,900.00%
ELVN Enliven Therapeutics	-0.43%	-11.65%	-9.25%	-8.68%	-29.00%
GPCR Structure Therapeutics	-1.18%	-1.95%	-13.94%	-35.07%	-52.96%
UPXI Upexi	-0.86%	-24.71%	+59.17%	-67.31%	-34.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	2.4608 of 5 stars	3.5	2.0	0.0	0.0	1.4	4.2	0.0
GPCR Structure Therapeutics	2.0502 of 5 stars	3.5	1.0	0.0	0.0	2.2	1.7	0.6
UPXI Upexi	3.769 of 5 stars	3.5	5.0	0.0	0.0	3.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	0.00	N/A	N/A	N/A
ELVN Enliven Therapeutics	3.00	Buy	$41.20	119.97% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	333.01% Upside
UPXI Upexi	3.00	Buy	$16.00	247.83% Upside

Current Analyst Ratings Breakdown

Latest UPXI, ELVN, GPCR, and BGM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
6/16/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$16.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$25.10M	33.31	N/A	N/A	$7.34 per share	1.17
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
UPXI Upexi	$16.56M	24.82	N/A	N/A	$6.24 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	-135.86%	-535.19%	-122.94%	9/29/2025 (Estimated)

Latest UPXI, ELVN, GPCR, and BGM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
5/16/2025	Q1 2025	UPXI Upexi	N/A	-$2.87	N/A	-$2.87	N/A	$3.16 million
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	1.82	1.45
ELVN Enliven Therapeutics	N/A	21.07	21.06
GPCR Structure Therapeutics	N/A	23.29	23.29
UPXI Upexi	0.31	0.37	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
ELVN Enliven Therapeutics	95.08%
GPCR Structure Therapeutics	91.78%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
ELVN Enliven Therapeutics	25.90%
GPCR Structure Therapeutics	9.43%
UPXI Upexi	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
UPXI Upexi	130	89.36 million	61.12 million	Optionable

UPXI, ELVN, GPCR, and BGM Headlines

Recent News About These Companies

Upexi, Inc. (NASDAQ:UPXI) Director Gene Salkind Buys 20,243 Shares

July 31 at 7:37 PM | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 20,243 Shares of Stock

July 31 at 6:37 AM | insidertrades.com

Upexi (NASDAQ:UPXI) Stock Price Down 9.9% - What's Next?

July 31 at 4:20 AM | marketbeat.com

Upexi to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 12th-14th

July 30 at 12:14 PM | manilatimes.netM

Upexi Secures $500M Equity Deal to Buy More Solana Despite Stock Drop

July 30 at 12:14 PM | thecurrencyanalytics.comT

Upexi enters $500M equity line agreement

July 29, 2025 | msn.com

Upexi, Inc. Announces $500 Million Equity Line Agreement with A.G.P. to Accelerate the Growth of its Solana Treasury Strategy

July 29, 2025 | manilatimes.netM

Solana Treasury firm Upexi secures $500M to acquire more SOL

July 29, 2025 | msn.com

Upexi Target of Unusually High Options Trading (NASDAQ:UPXI)

July 29, 2025 | americanbankingnews.com

Upexi (NASDAQ:UPXI) Shares Gap Up - Here's Why

July 28, 2025 | marketbeat.com

Traders Buy Large Volume of Call Options on Upexi (NASDAQ:UPXI)

July 28, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of Stock

July 25, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Purchases 11,000 Shares of Stock

July 25, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) CEO Buys 161,943 Shares of Stock

July 25, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of Stock

July 25, 2025 | insidertrades.com

Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million

July 25, 2025 | manilatimes.netM

Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

July 21, 2025 | globenewswire.com

Upexi Shares Slump After $50M Private Placement Offering Closes

July 17, 2025 | marketwatch.com

Upexi call volume above normal and directionally bullish

July 17, 2025 | msn.com

Upexi Shares Jump After Securing $150 Million in Convertible Notes Backed by Solana

July 17, 2025 | msn.com

Upexi Announces Closing of $50 Million Private Placement Equity Offering

July 15, 2025 | manilatimes.netM

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, ELVN, GPCR, and BGM Company Descriptions

BGM Group NASDAQ:BGM

$8.60 +0.14 (+1.65%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$8.26 -0.34 (-4.01%)

As of 08/1/2025 04:38 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Enliven Therapeutics NASDAQ:ELVN

$18.73 -0.08 (-0.43%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$18.72 -0.02 (-0.08%)

As of 08/1/2025 04:10 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Structure Therapeutics NASDAQ:GPCR

$17.59 -0.21 (-1.18%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$17.60 +0.02 (+0.09%)

As of 08/1/2025 04:32 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Upexi NASDAQ:UPXI

$4.60 -0.04 (-0.86%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.58 -0.01 (-0.33%)

As of 08/1/2025 07:59 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time